Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 11 Parkinson's papers of 1,081 | 0.67 |
| pathways Reactome | 11 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 3224
Sealed predictions
- NGFR in dopamine neurons, braak-0.37 (p 0.329) → -0.21 (p 0.586)receipt 3232
Swarm cases
receipt 3232: NGFR in dopamine neurons, braak
- power
- full sample -0.28 (p 0.261, n 18), 95% CI -0.66 to +0.22. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.25 (p 0.323, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.30 (p 0.221, n 18). could be the mix.
- skeptic
- leave-one-out range -0.38 to -0.19, sign flips 0; without severely affected donors -0.28 (p 0.261, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.61 (p 0.0067, n 18) vs -0.28 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NGFR in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NGFR · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.50 p 0.076 (needs p < 5.9e-4)
Receipts
loading the receipts